Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10692174 | 0.87 | OPRM1 (0.41) | OPRM1OPRL1SIGMAR1CARM1PRMT6 | |
| SCHEMBL15032475 | 0.87 | NAAA (0.39) | CARM1PRMT6HRH3 | |
| SCHEMBL6968463 | 0.80 | OPRM1 (0.43) | OPRM1OPRL1SIGMAR1CARM1PRMT6 | |
| SCHEMBL14899262 | 0.77 | — | — | |
| SCHEMBL8293595 | 0.76 | MEN1 (0.43) | CARM1PRMT6LMNA | |
| SCHEMBL13112943 | 0.76 | OPRM1 (0.48) | OPRM1OPRL1SIGMAR1CARM1PRMT6 | |
| SCHEMBL29338115 | 0.74 | OPRM1 (0.46) | OPRM1OPRL1SIGMAR1CARM1PRMT6 | |
| SCHEMBL23203461 | 0.72 | DRD2 (0.35) | OPRM1OPRL1SIGMAR1CARM1PRMT6 | |
| SCHEMBL23093104 | 0.72 | DRD2 (0.35) | OPRM1OPRL1SIGMAR1CARM1PRMT6 | |
| SCHEMBL21029509 | 0.72 | CTSL (0.41) | OPRM1OPRL1SIGMAR1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231143-B1 | 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431569-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431569-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20100267709-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-7452893-B2 | 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | MERCK & CO., INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1656379-B1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | THOMPSON WAYNE (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267709-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | OPRM1 4823/4885OPRL1 4639/4885SIGMAR1 4547/4885 |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | GRIN2B, GRIN3A, GRIN2A | OPRM1 62/4885OPRL1 69/4885SIGMAR1 460/4885 |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | GRIN2B, GRIN1, GRIN2A | OPRM1 173/4885OPRL1 45/4885SIGMAR1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.